Supply Agreement for Cardiomyopathy Treatment API with BridgeBio Pharma
-
Contract amount: approx. 55.99 billion KRW (USD 38,076,000, at 1,470.5 KRW/USD)
-
Contract period: 2026-05-05 to 2028-03-01 (about 22 months)
-
2.56% of total revenue (based on 2025 consolidated revenue of 2.18 trillion KRW)
-
Counterparty: BridgeBio Pharma, Inc. (US biotech firm)
-
Payment terms: net 30 days from invoice, no upfront payment
-
Sales region: undetermined
KOSPI Filing Information
-
Filing: Conclusion of a Single Sales and Supply Contract
-
Company: Yuhan (000100)
-
Submission: Yuhan Corporation
-
Receipt: 05-06-2026
-
Under KRX KOSPI Market Division